Crossmark Global Holdings Inc. Has $440,000 Holdings in STAAR Surgical (NASDAQ:STAA)

Crossmark Global Holdings Inc. lessened its holdings in shares of STAAR Surgical (NASDAQ:STAAGet Rating) by 2.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,230 shares of the medical instruments supplier’s stock after selling 170 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in STAAR Surgical were worth $440,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Raymond James & Associates boosted its holdings in shares of STAAR Surgical by 96.4% during the first quarter. Raymond James & Associates now owns 12,704 shares of the medical instruments supplier’s stock worth $1,015,000 after acquiring an additional 6,234 shares during the period. US Bancorp DE boosted its holdings in shares of STAAR Surgical by 23.5% during the first quarter. US Bancorp DE now owns 2,735 shares of the medical instruments supplier’s stock worth $219,000 after acquiring an additional 520 shares during the period. PNC Financial Services Group Inc. boosted its holdings in shares of STAAR Surgical by 18.6% during the first quarter. PNC Financial Services Group Inc. now owns 1,287 shares of the medical instruments supplier’s stock worth $102,000 after acquiring an additional 202 shares during the period. Rhumbline Advisers boosted its holdings in shares of STAAR Surgical by 2.2% during the first quarter. Rhumbline Advisers now owns 139,573 shares of the medical instruments supplier’s stock worth $11,153,000 after acquiring an additional 3,005 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in shares of STAAR Surgical by 10.5% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,445 shares of the medical instruments supplier’s stock worth $1,394,000 after acquiring an additional 1,663 shares during the period. Institutional investors and hedge funds own 97.55% of the company’s stock.

Wall Street Analysts Forecast Growth

STAA has been the subject of a number of research analyst reports. Canaccord Genuity Group boosted their price objective on STAAR Surgical from $76.00 to $79.00 and gave the stock a “buy” rating in a report on Friday. Sidoti upgraded STAAR Surgical from a “neutral” rating to a “buy” rating in a research note on Monday, November 7th. BTIG Research cut their price target on STAAR Surgical from $80.00 to $67.00 and set a “buy” rating for the company in a research note on Wednesday, December 28th. Mizuho initiated coverage on STAAR Surgical in a research note on Wednesday, October 12th. They issued a “buy” rating and a $85.00 price target for the company. Finally, Canaccord Genuity Group cut their price target on STAAR Surgical from $88.00 to $79.00 and set a “buy” rating for the company in a research note on Wednesday, November 30th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $86.80.

Insider Transactions at STAAR Surgical

In related news, major shareholder Broadwood Partners, L.P. purchased 51,985 shares of the stock in a transaction dated Tuesday, December 27th. The stock was bought at an average cost of $47.91 per share, for a total transaction of $2,490,601.35. Following the completion of the acquisition, the insider now owns 8,643,992 shares of the company’s stock, valued at $414,133,656.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 2.60% of the company’s stock.

STAAR Surgical Stock Performance

Shares of NASDAQ:STAA opened at $70.63 on Monday. The company has a fifty day moving average of $59.37 and a 200-day moving average of $73.09. The company has a market capitalization of $3.40 billion, a PE ratio of 92.94 and a beta of 1.05. STAAR Surgical has a 52-week low of $46.35 and a 52-week high of $112.27.

STAAR Surgical (NASDAQ:STAAGet Rating) last announced its quarterly earnings results on Wednesday, November 2nd. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.12. The company had revenue of $76.05 million during the quarter, compared to the consensus estimate of $74.95 million. STAAR Surgical had a net margin of 13.54% and a return on equity of 15.13%. The company’s revenue for the quarter was up 30.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.13 earnings per share. On average, equities analysts forecast that STAAR Surgical will post 0.83 EPS for the current fiscal year.

STAAR Surgical Profile

(Get Rating)

STAAR Surgical Co engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It specializes in refractive and cataract solutions. Its products include intraocular lens and implantable collamer lens.

Recommended Stories

Institutional Ownership by Quarter for STAAR Surgical (NASDAQ:STAA)

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.